The European injectable drug delivery technologies market was already worth a substantial $6.8 billion in 2012. But that number should soar to $12.4 billion by 2017, Markets and Markets estimates in a new report. Why the expansion? The report's authors see favorable reimbursement policies on injectable drugs and devices, improving technology and a surge of new biologics as helping to drive the trend. Higher rates of cancer and diabetes in Europe are also spurring market growth, the report concludes. While Germany accounted for the largest market share for injectable drug-delivery technologies in 2012, France is the fastest growing region. Item